105 related articles for article (PubMed ID: 20457140)
1. Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters.
Schumacher M; Hautzinger A; Rossmann A; Holzhauser S; Popovic D; Hertrampf A; Kuntz S; Boll M; Wenzel U
Biochem Pharmacol; 2010 Aug; 80(4):471-9. PubMed ID: 20457140
[TBL] [Abstract][Full Text] [Related]
2. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
3. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
4. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
Imai Y; Tsukahara S; Asada S; Sugimoto Y
Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
[TBL] [Abstract][Full Text] [Related]
5. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
8. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2.
Wang X; Morris ME
Drug Metab Dispos; 2007 Feb; 35(2):268-74. PubMed ID: 17093006
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
10. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
11. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
[TBL] [Abstract][Full Text] [Related]
12. [The mechanism of topotecan resistance in ovarian cancer cell line].
Jia P; Wu SB; Li F; Xu Q; Wu MF; Liao GN; Lu YP; Ma D
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):139-42. PubMed ID: 15196431
[TBL] [Abstract][Full Text] [Related]
13. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
14. Improved In vivo Effect of Chrysin as an Absorption Enhancer Via the Preparation of Ternary Solid Dispersion with Brij®L4 and Aminoclay.
Lee SH; Lee YS; Song JG; Han HK
Curr Drug Deliv; 2019; 16(1):86-92. PubMed ID: 30246640
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
[TBL] [Abstract][Full Text] [Related]
16. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
17. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
18. [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].
Jia P; Wu SB; Xu Q; Wu MF; Gao QL; Liao GN; Lu YP; Ma D
Ai Zheng; 2003 Dec; 22(12):1296-300. PubMed ID: 14693055
[TBL] [Abstract][Full Text] [Related]
19. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
20. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
